Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 34Squamous Cell Carcinoma of Head and Neck 22Uterine Cervical Neoplasms 19Lung Neoplasms 19Small Cell Lung Carcinoma 16Oropharyngeal Neoplasms 14Ovarian Neoplasms 12Carcinoma 10Urinary Bladder Neoplasms 9Stomach Neoplasms 9Mouth Neoplasms 9Laryngeal Neoplasms 9Fallopian Tube Neoplasms 9Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Mesothelioma, Malignant 7Medulloblastoma 7Breast Neoplasms 7Adenocarcinoma of Lung 7Neuroblastoma 6Nasopharyngeal Carcinoma 6Gallbladder Neoplasms 6Ganglioneuroblastoma 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Lymphoid Interstitial Pneumonia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4

Interventions

atezolizumab 5Etoposide 3Carboplatin 3Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1olaparib 1lipoarabinomannan 1cediranib 1bomedemstat 1Radiotherapy 1Radiation 1Platinum 1Lamivudine 1LB100 1Immunoglobulin G 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Platinum × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡